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Psychosis represents a set of symptoms against which current available treatments are not univer-
sally effective and are often accompanied by adverse side effects. Clinical management could poten-
tially be improved with a greater understanding of the underlying biology and subsequently with the
introduction of novel treatments. Since many clinical drug candidates are identified through in vivo
modelling, a deeper understanding of the pre-clinical field, might help us understand why translation
of results from animal models to inform mental health clinical practice has so far been weak. We set
out to give a shallow, but broad unbiased overview of experiments looking at the in vivo modelling of
psychotic disorders using a systematic review and meta-analysis. This protocol describes the exact
methodology we propose to follow in order to quantitatively review both studies characterizing a
model and those experiments that investigate the effects of novel therapeutic options. We are inter-
ested in assessing the prevalence of the reporting of measures to reduce risk of bias, and the internal
and external validity of the animal models and outcome measures used to validate these models. This
generation of strong empirical evidence has the potential to identify areas for improvement, make
suggestions for future research avenues, and ultimately inform what we think we know to improve
the current attrition rate between bench and bedside in psychosis research. A review like this will
also support the reduction of animal numbers used in research and the refinement of experiments to
maximize their value in informing the field.
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1 | GENERAL INFORMATION
We have used the proposed framework of Systematic Review Pro-
tocol for Animal Intervention Studies for the construction of this
protocol.1
1.1 | Title of the review
Improving our understanding of the in vivo modelling of psychotic
disorders.
1.2 | Stage of review at time of protocol
‡Present address: Royal Society of Chemistry, Burlington House, London, UK.
TABLE 1 Stage of review at time of protocol registration
Review stage Started Completed
Preliminary searches Yes Yes
Piloting of the study selection process Yes Yes
Formal screening of search results against
eligibility criteria
Yes Yes
Data extraction Yes No
Reporting of risk of bias (quality)
assessment
Yes No
Data analysis No No
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2 | OBJECTIVES
2.1 | Background
A mental disorder is defined as “any disorder or disability of the
mind” by The Mental Health Act 2007 for England and Wales2 and
as “mental illness, learning disability or personality disorder however
caused or manifested” by the Mental Health (Care and Treatment)
(Scotland) Act 2003.3 The definition in legal terms is therefore
very wide.
Clinically, this is also the case when considering international
classifications of mental disorders.4,5 Results from scientific literature
databases such as PubMed reveal that mental disorders at the
cognitive–emotional interface have received considerable and
increasing attention in the field of research over the last decade. Psy-
chotic mental disorders represent a severe category of these mental
disorders that, in England, have an overall incidence rate of about
32 per 100 000 person-years.6
These disorders are characterized by disorganized thinking and
perceptions that manifest themselves most commonly through
delusions and hallucinations. Other symptoms include abnormal
motor behaviour and negative symptoms such as apathy and
blunted affect (lack of emotional response), mostly associated with
schizophrenia and less so with other psychotic disorders.4,7
Broadly speaking, we can group psychotic disorders into 4 main
diagnostic categories, which include: (1) non-affective psychotic
disorders or disorders that are primarily considered to be psychotic
disorders and include examples like schizophrenia and schizoaffec-
tive disorder; (2) affective psychotic disorders, or mood disorders,
that present with psychotic features, like bipolar disorder or major
depressive disorder with psychotic features; (3) substance-induced
psychotic disorders that can be any substance- or medication-
induced psychosis; and (4) psychotic disorders due to a general
medical condition.4 Incidence rates among the English population
are the highest for non-affective psychoses (23 per 100 000
person-years), with schizophrenia accounting for about 15 per
100 000 person-years.6
Pharmacological treatment remains the cornerstone of the
clinical management of these disorders. These treatments were
introduced in the 1950s and a second generation of drugs in the
1990s, but whilst efficacious, they regrettably remain problematic
in terms of side effects and treatment resistance. Adverse side
effects accompany many anti-psychotic medications, and partial or
intermittent symptomatic relief is common, contributing to non-
compliance.8,9 Most concerning, however, is the group of indivi-
duals experiencing psychosis who are treatment-resistant.10 Our
understanding of the underlying mechanisms for these disorders
and how to ameliorate them remains poor, leading to a struggle in
the development of newer and better pharmacological treatment
options.11 Despite the large amount of preclinical research in the
field attempting to advance our understanding of these disorders,
development of novel drug classes for psychiatric diseases is still
an area of current weakness, and no real breakthroughs have been
made over the last decade.8
This shortcoming in translation of promising interventions
from bench to bedside could potentially be attributed to method-
ological flaws in preclinical experiments or the inadequacy of the
animal models themselves when it comes to representing the
human condition.12 Modelling disorders in animals is especially
difficult in neuropsychiatry as psychotic disorders are incredibly
heterogeneous in their symptomology and often present with
high levels of comorbidity.13,14 For this reason, more often than
not, emphasis tends to be focussed on modelling symptoms
rather than a disorder per se.13 Two ways in which researchers
have attempted to create models with face, construct and pre-
dictive validity for psychiatric disorders is by reiterating the
behavioural and cognitive abnormalities that are seen in the clini-
cal phenotype of the disorder or by mimicking the relevant neural,
neurochemical, molecular or anatomical aspects of the disorder in
question.13 Methods used to create animal models of schizophre-
nia, especially due to its highly complex and heterogeneous symp-
tomology, can be broadly clustered into 4 different groups:
pharmacological-, genetic-, developmental- and lesion-induced
models.15
While there has been no shortage of great appraisals of pre-
clinical models published over the last 2 decades in the form of
narrative reviews as a desperate attempt to bring together and try
and make sense of this exponentially growing field of research, we
believe that a sort of quantification of the animal research field
could be profitable in further improving our understanding of the
field.
Our aim is to improve our understanding of the role that animal
models play in the drug discovery process of psychotic disorders and
their validity by providing an unbiased summary of the field. This in
turn has the potential to inform the preclinical field of psychosis
research on which experiments work best and where improvements
can be made for future experiments. A better understanding of the
data that exists will inform what we think we know and thus help
improve the translation of knowledge between preclinical research
and clinical practice.
2.2 | Research question
2.2.1 | Specify the disease/health problem of interest
We are interested in studies looking at non-affective psychotic disor-
ders, affective psychotic disorders, substance-induced psychotic dis-
orders and psychotic disorders due to a general medical condition.
2.2.2 | Specify the population/species studied
We will not make any exclusions based on species and therefore
include studies investigating all animal species except humans.
2.2.3 | Specify the intervention/exposure
Our aim is to carry out an exploratory, broad review of the preclinical
field of psychosis, and therefore, we are not limiting our review to
any particular type of drugs or interventions but will aim to include
all interventions described in the literature as a method of model
induction for animal models of psychosis. For animal models of schiz-
ophrenia, due to the complexity of the clinical profile of the disorder,
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we expect to come across and therefore will include and differentiate
between interventions that can largely be grouped into 4 categories15:
experiments using genetic, lesion, pharmacological, developmental or
a combination of these type of interventions to model aspects recog-
nized to be representative of those in the human disorder.
2.2.4 | Specify the control population
For model-characterizing studies, we recognize a suitable control as
an animal that has not been exposed to the method of induction used
to create the model itself but has received a sham equivalent where
appropriate. Examples of this can be in the form of sham surgery per-
formed on the animal in place of a lesion or the administration of
saline or another vehicle used for the dissolution of the active com-
pound given to the model animal.
For treatment intervention studies, we consider a suitable control
to be an animal that has had the same exposure to the model of the
disorder as those that are given a treatment, but they have not been
exposed to the treatment being tested. Here, we will accept both
vehicle-treated and non-treated animals as an appropriate control.
2.2.5 | Specify the outcome measures
We will include studies looking at behavioural, anatomical, electro-
physiological and neurochemical outcomes initially to assess the over-
all quality of studies investigating animal models of psychotic
disorders; however, we plan to only extract data for experiments that
measure behavioural outcomes at this point in time.
2.2.6 | State your research question
We aim to provide an unbiased review of the field, and therefore, our
main research question is: what kind of in vivo model paradigms are
used to model psychotic disorders in animals? Moreover, we are
interested in how these experimental models and paradigms are cur-
rently being used to measure psychosis-related outcomes and how
they compare in terms of efficiency to modelling the human condi-
tion (ie, how good is the face and construct validity of these models?).
How well do results in this domain translate to results in human stud-
ies, especially in terms of predicting drug efficacy?
2.2.7 | Identify literature databases to search
We chose to search the life sciences and biomedical literature data-
base MEDLINE via the search engine PubMed to initially get a shal-
low, but broad, overview of the field.
2.2.8 | Define electronic search strategies
((((((((((((((((((((((((psychot*) OR psychosis) OR psychoses) OR paranoia)
OR paraphrenia) OR sensitive beziehungswahn) OR involutional para-
noid state) OR folie deux) OR cataton*) OR delusion*) OR hallucinat*)
OR schizotyp*) OR psychoactive) OR oneirophrenia) OR psychogen*)
OR bouffee delirante) OR hebephrenia) OR schizophren*) OR
schizoaffect*) OR manic stupor)) NOT comment*[Publication Type])
NOT case report*[Publication Type]) NOT letter*[Publication Type])
NOT review*[Publication Type]
Please find the full, expanded list of search words in the Supple-
mentary Information.
2.3 | Study selection
2.3.1 | Define screening phases
1. Pre-screening based on title and abstract.
2. Full-text screening, categorization and assessment of reporting of
experimental risk of bias.
3. Screening at level of data extraction for papers looking at beha-
vioural outcome measures.
The extraction of information regarding the reporting of experi-
mental risk of bias items is simply to obtain an overall picture of the
extent that these measures are reported in the literature and will not
be used as a tool to exclude papers from further analysis.
2.3.2 | Specify (a) the number of reviewers per screening
phase and (b) how discrepancies will be resolved
1. Two independent observers.
2. One observer and use of computer-based data mining as second
reviewer for reporting of experimental risk of bias.
3. Primarily one observer but 2 independent observers if possible.
In all phases, discrepancies will be resolved by an independent
third reviewer.
2.4 | Definition of all inclusion and exclusion criteria
based on
2.4.1 | Type of study (design)
Inclusion criteria: primary research articles.
Case reports, human studies, letters or comments, reviews, con-
ference and seminar abstracts without data or instances where data
being referred to is not clear from publication and studies where
there is no appropriate control group will be excluded.
2.4.2 | Type of animals/population
Inclusion criteria: Experiments looking at in vivo, whole animal models
of psychotic disorders that model any symptom recognized to be
related to psychotic disorders specified above, including transgenic
models of psychotic disorders. Animals of all ages, genders and spe-
cies will be considered.
Human, ex vivo or in vitro experiments; experiments using animal
models of other mental disorders that do not normally feature symp-
toms of psychosis (ie, affective disorders without psychotic symp-
toms); and in vivo experiments where no disease model is induced
before a treatment is tested (ie, pharmacological and toxicity studies
examining side effects of anti-psychotics drugs) will all be excluded.
2.4.3 | Type of intervention
Inclusion criteria: All types of interventions that aim to model psy-
chotic disorders in animals whether testing a treatment drug or sim-
ply characterizing the model. Moreover, we will consider all dosages,
durations and frequencies of treatment drug administrations.
Experiments where treatment interventions are given to healthy/
wild-type animals and not animals representing animal models of psy-
chotic disorders (ie, studies that look at pharmacological and toxicity
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side effects of anti-psychotics); experiments investigating drug with-
drawal in animals; and drug discrimination and other drug addiction
testing experiments will be excluded.
2.4.4 | Outcome measures
Inclusion criteria: In phases 1 and 2, we will include all publications
where behavioural, anatomical, electrophysiological and neurochem-
ical outcomes are described. We plan to extract data, foremost, for
behavioural outcomes; therefore, publications with all other outcome
measures will be retained and analysed for measures reportedly taken
to reduce the risk of experimental bias but will not be taken forward
for meta-analysis at this stage (phase 3).
Any other outcome measures, such as metabolic outcomes or
genetic analyses, will not be included.
2.4.5 | Language restrictions
Inclusion criteria: all languages.
Exclusion criteria: none.
2.4.6 | Publication date restrictions
Inclusion criteria: all dates.
Exclusion criteria: none.
2.4.7 | Sort and prioritize your exclusion criteria per
selection phase
We plan to exclude papers based on the following criteria at the fol-
lowing 3 stages of the review, split into a list of exclusion criteria
listed in order of importance:
Selection phase 1: Screening on basis of title and abstract
1. Not a primary research article (i.e. review, comment, editorial,
letter to the editor).
2. Study involving human participants and no animal data in
publication.
3. In vitro models.
4. No psychosis or aspect of schizophrenia induced.
5. No appropriate outcome measure (behavioural, anatomical,
electrophysiological or neurochemical).
All papers not excluded by the inclusion criteria above then go on to
phase 2 of the project.
Selection phase 2: Initial full-text screening
1. No induction of animal model of psychotic disorders.
2. If only behavioural outcomes reported; no outcomes measured
thought to be relevant to psychosis.
Papers not excluded by the inclusion criteria above go on to phase
3 of the project. At this stage, we will exclude papers not looking at
behavioural measures from further stages of the review; however, we
will not be excluding papers based on their score in our assessment
of the reporting of measures taken to reduce the risk of bias.
Selection phase 3: Final inclusion for data extraction and meta-
analysis
1. No behavioural outcome measure reported.
2. No appropriate control.
3. No n numbers or SD/SEM provided.
Papers not meeting the inclusion criteria at this phase of the project
will be excluded from the meta-analysis but will remain part of the
overall review of the field that describes the type of animal models
used, the types of outcomes assessed and the overall prevalence of
reporting of measures taken to reduce the risk of bias.
2.5 | Study characteristics to be extracted (for
assessment of external validity, reporting quality)
2.5.1 | Study ID
The following data specific to each study will be extracted: name of
first and corresponding authors, year of publication, title and
journal name.
2.5.2 | Study design characteristics
Number of animals in control and experimental groups will be
extracted. If n numbers are given as a range, the most conservative
estimate will be extracted.
2.5.3 | Animal model characteristics
If reported, we will collect data on the following details about animals
used in study: species, strain, gender, age at time of testing and
weight. Furthermore, information on which specific human disorder
the animal is considered to be modelling and details about the
method of disorder induction (including if transgenic and if a combi-
nation model) will be extracted. Time elapsed between model induc-
tion and outcome measurement is also of interest and will be
recorded.
2.5.4 | Intervention characteristics
We will extract information about the exact treatment tested, dosage
and mode of delivery of this treatment, as well as time when treat-
ment is administered, frequency of treatment administration and
length of treatment course. Time elapsed between treatment admin-
istration and outcome measurement will also be noted.
2.5.5 | Outcome measures
Of interest to us are the types of outcome measures that are meas-
ured in a study, for behavioural outcomes more specifically: the exact
name of each outcome that is measured and what animal behaviour
outcome measure is intended to quantify. Furthermore, for each out-
come, we will also extract the mean, SD or SEM and n for both the
control and experimental groups.
2.5.6 | Other
Where reported, we will also extract data on the number of excluded
animals and reason given, if any, for exclusion.
2.6 | Assessment of the reporting of measures
taken to reduce the risk of bias (internal validity)
(a) The number of reviewers assessing the reporting of risk of bias in
each study and (b) how discrepancies will be resolved.
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a. Risk of bias will be evaluated by scoring the reporting of measures
taken to reduce the risk of experimental bias within studies, prima-
rily by a single investigator and secondarily using computer-based
data mining tools.
b. Discrepancies will be resolved by a second independent reviewer.
2.6.1 | Criteria to assess the internal validity of included
studies
Reporting of measures taken to reduce the risk of bias will be
assessed using the previously used CAMARADES study quality
checklist,16 adapted to include the following items:
1. Reporting of randomization.
2. Evidence of blinded conduct of experiment.
3. Evidence of blinded assessment of outcome.
4. Statement of inclusion and exclusion criteria.
5. Reporting of sample size calculation.
6. Statement of possible conflict of interest.
7. Statement of compliance with animal welfare regulations.
8. Availability of a study protocol.
2.7 | Collection of outcome data
2.7.1 | For each outcome measure, define the type of
data to be extracted
We will extract all relevant comparisons of behavioural outcomes
within a study, including where animals of different ages, genders or
species are used. We expect this to be continuous data. We will
extract data separately for comparisons where any of these variables
differ in the group of animals being analysed from another compari-
son. We will also separately extract data for outcomes measured as a
result of different treatment regimens. For each outcome measure,
mean, SD or SEM and n numbers will be extracted for both experi-
mental and control groups.
2.7.2 | Methods for data extraction/retrieval
We will preferably and primarily extract numerical data from the
text of each publication (including if presented in a tabular for-
mat). In studies where data are only presented graphically, the
Adobe Reader Measuring Tool in Adobe Acrobat XI will be used to
extract numerical data. If any of the data we are interested in are
unclear from the publication or missing, we plan to contact
authors of the publication by email to obtain the correct data. In
the absence of a response from authors, data will be excluded
from analysis.
2.7.3 | Specify (a) the number of reviewers extracting
data and (b) how discrepancies will be resolved
a. Number of reviewers extracting data will primarily be one, but 2 if
resources allow.
b. Any discrepancies would be resolved by a third independent
reviewer.
2.7.4 | Specify (per outcome measure) how you are
planning to combine/compare the data
We plan on aggregating the data using a meta-analysis with subgroup
analyses separately for model characterizing and treatment-exploring
studies. When it comes to analysing the data, where data are
reported from independent groups of animals, we will treat data
reported as independent comparisons and will include them sepa-
rately in our meta-analysis. Where multiple behavioural outcomes are
reported from the same cohort of animals, we will nest data using the
fixed-effects model. This will be performed separately for compari-
sons looking at the performance of a model and comparing it to a
naïve animal and those where a treatment is being tested. Where a
control group serves more than one experimental group within a
study, we will correct the number of animals that are calculated in
our meta-analysis by dividing the number of animals that is reported
in the control group by the number of groups it serves within the
study. As we are interested in behavioural outcomes and how these
change over a period of time, we will calculate area under the curve
for different comparisons and will use data at all reported time points
to calculate an overall estimate for that comparison.17
2.7.5 | Specify (per outcome measure) how it will be
decided whether a meta-analysis will be performed
We consider the performance of a meta-analysis appropriate in the
case where we have more than 10 outcomes for an outcome
measure.
2.8 | If a meta-analysis seems feasible/sensible,
specify (for each outcome measure)
We will analyse studies characterizing the model and those looking at
the efficacy of a therapeutic intervention separately. The method
used for analysis will be identical for both, but we will look at differ-
ent study characteristics when assessing for potential sources of
heterogeneity.
2.8.1 | The effect measure to be used
Where the performance of a normal, unlesioned, wild-type animal is
known or can be inferred in at least 80% of experiments, we will use
normalized mean difference meta-analysis as the primary outcome,
with standardized mean difference as a sensitivity analysis. If the per-
formance of a normal, unlesioned, wild-type animal is unknown or
can be inferred in less than 80% of experiments, we will use standar-
dized a mean difference meta-analysis as the primary outcome, with
normalized mean difference as a sensitivity analysis. We will combine
multiple outcomes from the same experimental cohorts using fixed-
effects meta-analysis.17
2.8.2 | The statistical model of analysis
We will use the random-effects model to pool and analyse effect
sizes from different comparisons as we expect there to be a consider-
able amount of heterogeneity between studies due to the large diver-
sity in study design. This will thus take into account both within-
study (sampling error) as well as between-study variance.17 While the
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meta-analysis will provide a global estimate of efficacy of anti-
psychotic agents, this is of very limited utility, and a much more
important finding is evidence for any heterogeneity to more closely
identify which aspects of anti-psychotic treatments and experimental
designs are associated with different levels of efficacy.
2.8.3 | The statistical methods to assess heterogeneity
Which study characteristics will be examined as potential source of
heterogeneity?
We will assess differences between the reporting of risk of bias qual-
ity assessment subgroups, including each individual quality item and
number of study quality checklist items scored by publication.
We also plan to assess differences between study characteristics
assessment subgroups, which will be different for model characteriz-
ing and treatment exploring experiments (Table 2).
2.8.4 | Any sensitivity analyses you propose to perform
Where we use normalized mean difference meta-analysis as the pri-
mary outcome, we will use standardized mean difference as a sensitiv-
ity analysis. Where we use standardized mean difference meta-analysis
as the primary outcome, we will use normalized mean difference as a
sensitivity analysis.
2.8.5 | Other details of the meta-analysis
For partitioning of heterogeneity, we will use the Holm-Bonferroni
method to adjust critical values of P separately for quality items and
study design items in subgroup analyses.
2.8.6 | The method for assessment of publication bias
Risk of publication bias will be evaluated using funnel plot assessment
and Egger’s regression.18,19 Trim and fill analysis20 using STATA will
be used to identify possible missing studies in the literature. These
evaluations will be conducted independently for each outcome meas-
ure using non-nested data.
ACKNOWLEDGEMENTS
We acknowledge the contributions of F. Cramond, A. Sinclair,
R. O’Shea, M. Dingwall, H. Vesterinen and A. Bannach-Brown, all
affiliates of the University of Edinburgh, in their help with the project
so far. The project receives intramural support from SyRF, an infra-
structure award from the National Centre for the Replacement,
Refinement & Reduction of Animals in Research (NC3Rs).
Conflict of interest
M.R.M. and E.S.S. are editors of EBPM.
REFERENCES
1. De Vries RBM, Hooijmans CR, Langendam MW, et al. A protocol for-
mat for the preparation, registration and publication of systematic
reviews of animal intervention studies. Evid Based Preclin Med.
2015;2:1–9.
2. Great Britain and Department of Health. Mental Health Act 2007:
Consultation on Secondary Legislation. London, England: Dept. of
Health; 2007.
3. Franks RA, Cobb DW. Mental Health (Care and Treatment) (Scotland)
Act 2003. Edinburgh, England: Thompson/W. Green; 2005.
4. American Psychiatric A, American Psychiatric A, Force DSMT. Diag-
nostic and Statistical Manual of Mental Disorders : DSM-5. American
Psychiatric Association: Washington, DC; 2013.
5. World Health Organization. Organization WH, ed. The ICD-10 Classifi-
cation of Mental and Behavioural Disorders: Clinical Descriptions and
Diagnostic Guidelines. Geneva, Switzerland: World Health Organiza-
tion; 1992.
6. Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophre-
nia and other psychoses in England, 1950–2009: a systematic review
and meta-analyses. PLoS One. 2012;7:e31660.
7. van Os J, Kapur S. Schizophrenia. Lancet (London, Engl).
2009;374:635–645.
8. Geyer MA, Olivier B, Joëls M, Kahn RS. From antipsychotic to anti-
schizophrenia drugs: role of animal models. Trends Pharmacol Sci.
2012;33:515–521.
9. Kane JM, Correll CU. Past and present progress in the pharmacologic
treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115–1124.
10. Kapur S, Mamo D. Half a century of antipsychotics and still a central
role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psy-
chiatry. 2003;27:1081–1090.
11. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for
schizophrenia: a critical review of pharmacology and mechanisms of
action of antipsychotic drugs. Mol Psychiatry. 2005;10:79–104.
12. van der Worp HB, Howells DW, Sena ES, et al. Can animal models
of disease reliably inform human studies? PLoS Med. 2010;7:
e1000245.
13. Fernando AB, Robbins TW. Animal models of neuropsychiatric disor-
ders. Annu Rev Clin Psychol. 2011;7:39–61.
TABLE 2 Study characteristics assessment subgroups that will be examined as potential sources of heterogeneity
Model characterizing studies Treatment exploring studies
Species of animals used Species of animals used
Gender of animals used Gender of animals used
Specific intervention used to induce model Specific intervention used to induce model
For schizophrenia models: Method of model induction (ie, developmental,
genetic, pharmacological, lesion or combination)
For schizophrenia models: Method of model induction (ie, developmental,
genetic, pharmacological, lesion or combination)
Extent of lesion/dose of drug used to induce model Extent of lesion/dose of drug used to induce model
Outcome being measured Outcome being measured
Exact methods used to assess outcome measure Exact methods used to assess outcome measure
Time of outcome measurement (in relation to model induction) Time of outcome measurement (in relation to model induction and/or
treatment administration)
Treatment given
Dose of treatment given
Time of administration
BAHOR ET AL. 15
14. Geyer MA, Moghaddam B. Animal models relevant to schizophrenia
disorders. In: Davis KLCD, Coyle JT, Nemeroff C, eds. Neuropsycho-
pharmacology: The Fifth Generation of Progress: An Official Publication
of the American College of Neuropsychopharmacology. Pennsylvania,
PA: Lippincott Williams & Wilkins; 2002.
15. Jones CA, Watson DJG, Fone KCF. Animal models of schizophrenia.
Brit J Pharmacol. 2011;164:1162–1194.
16. Macleod MR, O’Collins T, Howells DW, Donnan GA. Pooling of ani-
mal experimental data reveals influence of study design and publica-
tion bias. Stroke. 2004;35:1203–1208.
17. Vesterinen HM, Sena ES, Egan KJ, et al. Corrigendum to Meta-
analysis of data from animal studies: a practical guide. J Neurosci
Methods. 2015;221:92–102.
18. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. Br Med J. 1997;315:
629–634.
19. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR.
Publication bias in reports of animal stroke studies leads to major
overstatement of efficacy. PLoS Biol. 2010;8:e1000344.
20. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method
of testing and adjusting for publication bias in meta-analysis. Biomet-
rics. 2000;56:455–463.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: Bahor Z, Nunes-Fonseca C, Thom-
son LDG, Sena ES, and Macleod M, Improving our under-
standing of the in vivo modelling of psychotic disorders: A
protocol for a systematic review and meta-analysis, Evidence-
based Preclinical Medicine, 2017. doi: 10.1002/ebm2.22
16 BAHOR ET AL.
